Quoting Vivek Subbiah, Chief of Early-Phase Drug Development, on Twitter:
“Final free version just published In European Journal of Cancer for your Friday reading
Lurbinectedin was approved for Small cell Lung in USA & now is also approved in Canada, Australia, Singapore, the United Arab Emirates, Qatar, South Korea, Ecuador, Mexico, Israel & Switzerland
We also showed results of other cohorts of this basket trial showing anti-tumor activity in
Ewing sarcoma, leading to inclusion in the National Comprehensive Cancer Network guidelines
Germline BRCA1/2 metastatic breast cancer.
This paper reports on Safety of approved dose in 554 patients with advanced solid tumors
Most common toxicity was transient and reversible myelosuppression
Non-hematological events were mostly mild/moderate.”
For the article click here.
Source: Vivek Subbiah/Twitter